Haem administration in myelodysplastic syndromes: a possible mechanism of action.
Chalevelakis
G
G
Yalouris
A G
AG
D001120:Arginine / Q000627:therapeutic use*; D005914:Globins / Q000096:biosynthesis; D006418:Heme / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy*; D012156:Reticulocytes / Q000187:drug effects / Q000378:metabolism; D017085:alpha-Thalassemia / Q000097:blood / Q000188:drug therapy; D017086:beta-Thalassemia / Q000097:blood / Q000188:drug therapy
D006418:Heme; D005914:Globins; D001120:Arginine; C048849:heme arginate